Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability
| Autor: | Richard D. Egleton, Terrence J. Gillespie, Ken A. Witt, Thomas P. Davis, Jason D. Huber |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Brain uptake
chemistry.chemical_classification Physiology Central nervous system Biological Availability Peptide Biology Pharmacology Blood–brain barrier Biochemistry Bioavailability Cellular and Molecular Neuroscience Endocrinology medicine.anatomical_structure chemistry Blood-Brain Barrier medicine Blood brain barrier permeability Peptide drug Peptides Biological availability |
| Zdroj: | Peptides. 22(12) |
| ISSN: | 0196-9781 |
| Popis: | Peptides have the potential to be potent pharmaceutical agents for the treatment of many central nervous system derived maladies. Unfortunately peptides are generally water-soluble compounds that will not enter the central nervous system, via passive diffusion, due to the existence of the blood-brain barrier. Peptides can also undergo metabolic deactivation by peptidases, thus further reducing their therapeutic benefits. In targeting peptides to the central nervous system consideration must be focused both on increasing bioavailability and enhancing brain uptake. To date multiple strategies have been examined with this focus. However, each strategy comes with its own complications and considerations. In this review we assess the strengths and weaknesses of many of the methods currently being examined to enhance peptide entry into the central nervous system. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect